Loading...
•
Dec 31, 2023
Voyager Therapeutics Q4 2023 Earnings Report
Voyager Therapeutics' financial results for Q4 2023 were reported, highlighted by collaboration revenue and net income.
Key Takeaways
Voyager Therapeutics reported a strong fourth quarter, marked by a significant increase in collaboration revenue primarily due to the Novartis agreement, leading to a net income of $56.4 million. The company's pro-forma cash position as of December 31, 2023, was approximately $431 million, adjusted for the Novartis agreements and public offering.
Voyager had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for the Novartis agreements and public offering.
Lead development candidates were selected in Friedreich’s ataxia gene therapy program with Neurocrine Biosciences and in wholly-owned SOD1 ALS gene therapy program.
Strategic collaboration and capsid license agreement with Novartis was entered into.
Voyager expects to advance at least four wholly-owned and partnered programs into the clinic by the end of next year.
Voyager Therapeutics
Voyager Therapeutics
Voyager Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Voyager expects its cash, cash equivalents, and marketable securities, including proceeds from the Novartis Collaboration and Licensing Agreement and Stock Purchase Agreement, along with reimbursements for development costs and near-term milestones, to be sufficient to meet planned operating expenses and capital expenditure requirements into 2027.
Positive Outlook
- Advancing AAV-based gene therapy programs.
- Advancing tau antibody program.
- Achievement of preclinical and clinical development milestones.
- Advancing gene therapy product candidates under the Neurocrine and Novartis collaborations.
- Negotiating and completing licensing or collaboration agreements with other parties.
Challenges Ahead
- Continued development of Voyager’s technology platforms.
- Initiation and conduct preclinical studies in animal models.
- Development by third parties of capsid identification platforms that may be competitive to Voyager’s TRACER capsid discovery platform.
- Voyager’s ability to create and protect intellectual property rights.
- The sufficiency of cash resources to fund operations and pursue corporate objectives.